ArticleEuropean journal of pain (London, England)2026
SARS-CoV-2 Spike Peptides Trigger Nociceptive Responses Through Spinal TLR4 Pathways.
Article in European journal of pain (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPain is a common neurological manifestation of COVID-19, yet the mechanisms by which SARS-CoV-2 spike protein fragments contribute to nociceptive processing remain poorly understood. We investigated whether spike-derived peptides directly activate spinal neuroimmune pathways involved in pain signalling.
methodsMale C57BL/6 mice received intrathecal administration of three synthetic SARS-CoV-2 spike-derived peptides (PSPD2001, PSPD2002 or PSPD2003) or saline. Mechanical nociception was assessed using the von Frey test. The involvement of spinal Toll-like receptor 4 (TLR4), microglia and p38 MAPK/NF-κB signalling was investigated using pharmacological antagonists, TLR4 knockout mice, RT-qPCR, ELISA, immunofluorescence, CX3CR1
resultsAll spike-derived peptides induced mechanical nociception, with PSPD2003 producing the most pronounced response. PSPD2003 increased spinal TLR4 expression, elevated TNF-α and IL-6 levels and promoted activation of dorsal horn microglia, demonstrated by increased TMEM119- and CX3CR1-positive cells. These nociceptive and neuroinflammatory effects were abolished by pharmacological inhibition of TLR4, microglia, p38 MAPK and NF-κB signalling, as well as in TLR4
conclusionsThese findings identify a previously unrecognized neuroimmune mechanism whereby a SARS-CoV-2 spike-derived peptide triggers spinal nociception through TLR4-dependent microglial activation and downstream p38 MAPK/NF-κB signalling, highlighting the spinal TLR4-microglia axis as a potential therapeutic target for COVID-19-associated and post-viral pain. SIGNIFICANCE STATEMENT: This study provides the first evidence that SARS-CoV-2 spike-derived peptides directly activate a spinal TLR4-dependent neuroimmune pathway to induce nociception. By integrating behavioural, pharmacological, genetic, cellular and computational approaches, it identifies microglial activation and p38 MAPK/NF-κB signalling as key mechanisms linking viral peptides to pain, providing a mechanistic framework for COVID-19- and post-viral pain and supporting TLR4 as a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.